BNP Paribas Arbitrage SA lifted its stake in Vitamin Shoppe, Inc (NYSE:VSI) by 2.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,242 shares of the specialty retailer’s stock after purchasing an additional 192 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Vitamin Shoppe were worth $108,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc lifted its position in shares of Vitamin Shoppe by 9.3% in the second quarter. Legal & General Group Plc now owns 44,555 shares of the specialty retailer’s stock worth $518,000 after purchasing an additional 3,789 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Vitamin Shoppe by 0.8% in the second quarter. Arizona State Retirement System now owns 12,460 shares of the specialty retailer’s stock worth $145,000 after purchasing an additional 100 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Vitamin Shoppe by 34.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 262,123 shares of the specialty retailer’s stock worth $3,054,000 after purchasing an additional 67,362 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in shares of Vitamin Shoppe by 80.6% in the second quarter. Canada Pension Plan Investment Board now owns 236,900 shares of the specialty retailer’s stock worth $2,760,000 after purchasing an additional 105,700 shares in the last quarter. Finally, Texas Permanent School Fund lifted its position in shares of Vitamin Shoppe by 0.8% in the second quarter. Texas Permanent School Fund now owns 17,389 shares of the specialty retailer’s stock worth $203,000 after purchasing an additional 145 shares in the last quarter. 96.86% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/01/vitamin-shoppe-inc-vsi-shares-bought-by-bnp-paribas-arbitrage-sa.html.

VSI has been the subject of a number of research analyst reports. Bank of America Corporation reissued an “underperform” rating and issued a $5.00 price target (down from $5.50) on shares of Vitamin Shoppe in a research report on Wednesday, August 23rd. Zacks Investment Research lowered shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th. ValuEngine downgraded Vitamin Shoppe from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Deutsche Bank AG restated a “hold” rating and issued a $7.00 price objective (down previously from $14.00) on shares of Vitamin Shoppe in a report on Thursday, August 10th. Finally, Barclays PLC dropped their price objective on Vitamin Shoppe from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, August 10th. Four research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $12.43.

Vitamin Shoppe, Inc (NYSE VSI) opened at 5.35 on Friday. The firm’s market cap is $124.24 million. Vitamin Shoppe, Inc has a one year low of $4.95 and a one year high of $28.41. The firm’s 50-day moving average price is $6.38 and its 200 day moving average price is $12.76.

Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings results on Wednesday, August 9th. The specialty retailer reported $0.23 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.39 by ($0.16). The company had revenue of $304.84 million for the quarter, compared to analyst estimates of $314.74 million. Vitamin Shoppe had a positive return on equity of 8.33% and a negative net margin of 11.98%. The firm’s revenue for the quarter was down 8.4% compared to the same quarter last year. During the same period last year, the firm earned $0.55 EPS. On average, equities research analysts forecast that Vitamin Shoppe, Inc will post $0.79 EPS for the current year.

In related news, Director John D. Bowlin purchased 40,000 shares of the stock in a transaction on Friday, August 25th. The shares were purchased at an average price of $5.50 per share, with a total value of $220,000.00. Following the transaction, the director now directly owns 56,028 shares of the company’s stock, valued at $308,154. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 1.07% of the stock is owned by insiders.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Institutional Ownership by Quarter for Vitamin Shoppe (NYSE:VSI)

Receive News & Stock Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related stocks with our FREE daily email newsletter.